Johnson & Johnson
- Targets
- 3
- Filings
- 7
- Median premium
- 30%
- First filing
- Jan 19, 2024
- Latest filing
- Feb 18, 2025
Targets
| Company | Score before deal | Score now | Filings | Latest |
|---|---|---|---|---|
| Intra-Cellular Therapies, Inc. | 1 / 7 | — | 3 | Feb 18, 2025 |
| Shockwave Medical, Inc. | 1 / 7 | — | 2 | Apr 29, 2024 |
| Ambrx Biopharma, Inc. | — | — | 2 | Jan 29, 2024 |
Deal filings
| Filed | Company | Form | Price | Premium |
|---|---|---|---|---|
| Feb 18, 2025 | Intra-Cellular Therapies, Inc. | DEFM14A | $132.00 | — |
| Feb 5, 2025 | Intra-Cellular Therapies, Inc. | PREM14A | $132.00 | — |
| Jan 13, 2025 | Intra-Cellular Therapies, Inc. | 8-K | — | — |
| Apr 29, 2024 | Shockwave Medical, Inc. | DEFM14A | $335.00 | — |
| Apr 18, 2024 | Shockwave Medical, Inc. | PREM14A | $335.00 | — |
| Jan 29, 2024 | Ambrx Biopharma, Inc. | DEFM14A | $28.00 | — |
| Jan 19, 2024 | Ambrx Biopharma, Inc. | PREM14A | $28.00 | 30% |